First human test for new lung scarring drug begins
Disease control
Completed
This was the first study in humans to test the safety of an experimental drug called HuL001 for idiopathic pulmonary fibrosis (IPF), a serious disease that causes permanent lung scarring. The study first gave single doses to 12 healthy volunteers to check for side effects, then g…
Phase: PHASE1 • Sponsor: HuniLife Biotechnology, Inc. • Aim: Disease control
Last updated Apr 02, 2026 05:26 UTC